Jaka jest cena za Scilex Holding Company (SCLX)

Cena za Scilex Holding Company (SCLX) wynosi $5.61

Jaka jest kapitalizacja rynkowa dla Scilex Holding Company (SCLX)

Kapitalizacja rynkowa dla Scilex Holding Company (SCLX) wynosi $47.65M

Scilex Holding Company (SCLX) Stopa Dywidendy

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.

Rok	Stopa dywidendy	Zmień
Za mało danych dla podanych dat.

Rok

Stopa dywidendy

Zmień

Za mało danych dla podanych dat.

Firma	Stopa dywidendy	Kraj
Eli Lilly and Company LLY.US	0.57%	US
Johnson & Johnson JNJ.US	2.01%	US
AbbVie Inc. ABBV.US	2.74%	US
Roche Holding AG RO.SW	2.69%	CH
Merck & Co., Inc. MRK.US	2.47%	US

Firma

Stopa dywidendy

Kraj

Eli Lilly and Company

LLY.US

0.57%

Johnson & Johnson

JNJ.US

2.01%

AbbVie Inc.

ABBV.US

2.74%

Roche Holding AG

RO.SW

2.69%

Merck & Co., Inc.

MRK.US

2.47%

Scilex Holding Company

SCLX

Kategoria